FRM
PGNX

Fox Run Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Fox Run Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18,678
Closed -$150K – 916
2018
Q2 		$150K Sell
18,678
-4,071
-18% -$31.1K 0.05% 606
2018
Q1 		$170K Buy
22,749
+5,999
+36% +$39.9K 0.04% 649
2017
Q4 		$100K Buy
+16,750
New +$102K 0.03% 624
2017
Q3 		– Sell
-49,300
Closed -$335K – 957
2017
Q2 		$335K Buy
49,300
+29,768
+152% +$220K 0.12% 365
2017
Q1 		$184K Buy
19,532
+7,632
+64% +$76.2K 0.08% 499
2016
Q4 		$103K Buy
+11,900
New +$88K 0.05% 463

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Fox Run Management's PGNX Position: Q3 2018 in Review

Fox Run Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 18,678 shares — an estimated $150K sold.

Fox Run Management first reported a position in PGNX in Q4 2016 and held it in 6 quarters. The position peaked at $335K in Q2 2017. 149 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

  • Fox Run Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Fox Run Management sold 18,678 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $150K.
  • Fox Run Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 6 quarters.
  • Fox Run Management's Progenics Pharmaceuticals Inc position peaked at $335K in Q2 2017.
  • 149 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Fox Run Management's 13F filing for Q3 2018, filed 5 Oct 2018.